BMS’s strong 2Q outshines mixed Opdivo data in 1L NSCLC

Investors shrugged off mixed data for Opdivo in first-line lung cancer as Bristol-Myers climbed $2.17 to $45.40 on Thursday on 2Q19 earnings that beat the Street's expectations.

Bristol-Myers Squibb Co. (NYSE:BMY) reported postmarket data Wednesday from two separate parts of the Phase III CheckMate -227 trial to treat first-line NSCLC that means its competitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) will likely retain its stranglehold on the first-line setting...